Adavosertib,Afatinib Dimaleate,Binimetinib,Capivasertib,Copanlisib,Copanlisib Hydrochloride,Crizotinib,Dabrafenib,Defactinib,Defactinib Hydrochloride,Erdafitinib,Ipatasertib,Larotrectinib,Larotrectinib,Sulfate,Nivolumab,Osimertinib,Pertuzumab,Relatlimab,Sapanisertib,Taselisib,Trametinib,Trastuzumab,Trastuzumab Emtansine,Ulixertinib,Vismodegib
Astrazeneca,Boehringer Ingelheim,ono pharmacueticals,pierre fabre,pfizer,Otsuka,Bayer,Novartis,verastem,janssen,Roche,Bms,calithera,biomed valley discoveries
['trametinib', 'nci-match', 'match study', 'dabrafenib', 'match trial']
nci-match study showed tissue agnostic activity 7/10 dabrafenib and trametinib in patients with tumors with braf v600e mutations: results of the nci-match trial subprotocol h #aacr23 
Oncologist | Associate Prof | Executive Director-Research, MD Anderson Cancer Network | Medical Director, Clinical Center for Targeted Therapy. Tweets = my own.